---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-22-000049"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2022-07-12T23:59:59+00:00"
generated_at: "2026-06-24T16:50:21.829243+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Allogene appoints Stephen Mayo, Ph.D. to Board; board expands to 12

## Summary
- Board increased from 11 to 12; Mayo appointed as Class III director, term expires at 2024 annual meeting.
- Annual cash retainer of $40,000 for board service under non-employee director compensation policy.
- Initial equity grants: option and RSU each with $425,000 grant date value, vesting over 3 years and 3 annual installments.
- Director eligible for annual automatic option/RSU grants with $425,000 value on each annual meeting date.
- Equity grants accelerate fully upon change in control.

## SEC filing metadata
- accession: 0001737287-22-000049
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2022-07-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000049/0001737287-22-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000049/allo-20220708.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-22-000049
- JSON: https://secwatch.observer/filing/0001737287-22-000049.json
- Plain text: https://secwatch.observer/filing/0001737287-22-000049.txt

## Key facts
- Executive change
  Stephen Mayo was appointed as Director at Allogene Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On July 8, 2022, the Board of Directors (the “Board”) of Allogene Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased the authorized number of directors on the Board from eleven to twelve, and appointed Stephen Mayo, Ph.D. as a Class III director of the Company to fill the newly created vacancy, effective immediately, with a term of office expiring at the Company’s 2024 annual meeting of stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000049/0001737287-22-000049-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.